Impact of opportunistic disease on survival in patients with HIV infection

Objective:To assess the impact of opportunistic diseases on survival in patients with HIV disease. Methods:A cohort of 2081 patients followed for a mean of 30 months was studied. Time-dependent Cox proportional hazards analyses were performed using incident opportunistic diseases and CD4 cell counts as independent variables. Results:During follow-up, 730 (35%) patients died. The occurrence of Pneumocystis carinii pneumonia (PCP), cytomegalovirus (CMV) disease, Mycobacterium avium complex (MAC) disease, Candida esophagitis, Kaposi's sarcoma, lymphoma, progressive multifocal leukoencephalopathy (PML), dementia, wasting, toxoplasmosis, and cryptosporidiosis were all significantly associated with death, independently of CD4 cell count (all P < 0.001 for opportunistic diseases controlling for CD4 cell count). The magnitude of increased risk was greatest for lymphoma [relative hazard (RH), 7.2], PML (RH, 3.9), MAC (RH, 3.0) and CMV (RH, 2.2). Cryptococcosis (RH, 0.94) and herpes zoster (RH, 0.85) were not associated with death. In a multivariate Cox proportional hazards analysis, MAC [RH, 2.56; 95% confidence interval (CI), 2.1–3.1], CMV (RH, 1.63; 95% CI, 1.3–2.1), toxoplasmosis (RH, 1.85; 95% CI, 1.3–2.6), PCP (RH, 1.29; 95% CI, 1.1–1.5), and CD4 cell count were significantly associated with death. Patients who had opportunistic diseases had significantly greatly monthly declines in CD4 counts (−11 × 106/l per month) than those who did not (−6 × 106/l per month; P < 0.001). Conclusion:Most opportunistic diseases increase the risk of death independently of CD4 cell count. These data support the hypothesis that opportunistic diseases enhance HIV pathogenesis and further underscore the importance of prophylaxis.

[1]  R. Dewar,et al.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[2]  R. Chaisson,et al.  Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.

[3]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[4]  J. Phair,et al.  Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study. , 1993, The New England journal of medicine.

[5]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[6]  T. Perneger,et al.  Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. Swiss HIV Cohort Study Group. , 1996, The Journal of infectious diseases.

[7]  G Molenberghs,et al.  Patterns of opportunistic infections in patients with HIV infection. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[8]  J. Phair,et al.  Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). , 1994, Journal of acquired immune deficiency syndromes.

[9]  R. Chaisson,et al.  Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group. , 1992, Archives of internal medicine.

[10]  E. Vittinghoff,et al.  The impact of Mycobacterium avium complex bacteremia and its treatment on survival of AIDS patients--a prospective study. , 1994, The Journal of infectious diseases.

[11]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[12]  P. Hartigan,et al.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. , 1996, The New England journal of medicine.

[13]  D.,et al.  Regression Models and Life-Tables , 2022 .

[14]  L. Saravolatz,et al.  Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons. , 1996, The Journal of infectious diseases.

[15]  J. Bartlett.  Protease Inhibitors for HIV Infection , 1996, Annals of Internal Medicine.

[16]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[17]  J. Mellors,et al.  Quantitation of HIV-1 RNA in Plasma Predicts Outcome after Seroconversion , 1995, Annals of Internal Medicine.

[18]  Richard D Moore,et al.  Pneumocystis Prophylaxis and Survival in Patients With Advanced Human Immunodeficiency Virus Infection Treated With Zidovudine , 1992 .

[19]  R. Chaisson,et al.  Race, sex, drug use, and progression of human immunodeficiency virus disease. , 1995, The New England journal of medicine.

[20]  C H Fox,et al.  Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. , 1996, The New England journal of medicine.

[21]  D. Weissman,et al.  Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. , 1996, Journal of immunology.

[22]  J. Margolick,et al.  The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. , 1996, The Journal of infectious diseases.

[23]  J. Ward,et al.  Trends in Infectious Diseases and Cancers among Persons Dying of HIV Infection in the United States from 1987 to 1992 , 1995, Annals of Internal Medicine.

[24]  H. Waskin,et al.  A Randomized Trial Comparing Fluconazole with Clotrimazole Troches for the Prevention of Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection , 1995 .

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  J. Phair,et al.  Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS , 1991, The Lancet.

[27]  R. Chaisson,et al.  Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS , 1995, AIDS.

[28]  S. Zeger,et al.  Longitudinal data analysis using generalized linear models , 1986 .

[29]  L. La Voie,et al.  Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. , 1988, Journal of the American Medical Association (JAMA).

[30]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[31]  A. LaMarca,et al.  A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. , 1996, The New England journal of medicine.